Crohn’s & Colitis 360

Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease

Digestive Disease Week (DDW) 2020

Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2 (CB2), Reduces Visceral Hypersensitivity in Mice

Digestive Disease Week (DDW) 2019

Olorinab Reduces Visceral Hypersensitivity in Animal Models

Safety and Efficacy of Olorinab in Ph2a Study in Chronic Abdominal Pain Associated w-CD

14th Congress of European Crohn’s and Colitis Organisation (ECCO) 2019

Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly-Selective, Cannabinoid Receptor 2 Agonist in a Phase 2a Study in Chronic Abdominal Pain Associated with Crohn’s Disease

Crohn’s & Colitis Congress 2019

Olorinab, a Peripherally Restricted, Highly Selective Agonist of the Cannabinoid Receptor Type 2 for the Management of Visceral Pain in Inflammatory Bowel Disease (IBD)—Preclinical and Early Clinical Development

International Association for the Study of Pain (IASP) World Congress 2018

APD371, a Peripherally Restricted, Highly Selective, Full Agonist of the Cannabinoid Receptor 2 (CB2) Receptor, Reduces Colitis-Induced Visceral Hypersensitivity in Rats

Congress: American Pain Society (APS) Annual Scientific Summit 2018

APD371: A Potent, Highly Selective, Full Agonist of the Human CB2 Receptor With Sustained Analgesic Effects in Rodents

Safety, Tolerability, and Pharmacokinetics of APD371, a Highly Selective CB2 Agonist, in Healthy Adults

1 2

For Medical Information, contact us at medinfo@arenapharm.com